106 related articles for article (PubMed ID: 14623893)
21. STAT3 selectively interacts with Smad3 to antagonize TGF-β signalling.
Wang G; Yu Y; Sun C; Liu T; Liang T; Zhan L; Lin X; Feng XH
Oncogene; 2016 Aug; 35(33):4388-98. PubMed ID: 26616859
[TBL] [Abstract][Full Text] [Related]
22. Tissue Expression Analysis and Characterization of Smad3 Promoter in Bovine Myoblasts and Preadipocytes.
Zhang L; Ning Y; Li P; Guo H; Zan L
DNA Cell Biol; 2018 Jun; 37(6):551-559. PubMed ID: 29672161
[TBL] [Abstract][Full Text] [Related]
23. Transcriptional control by the TGF-beta/Smad signaling system.
Massagué J; Wotton D
EMBO J; 2000 Apr; 19(8):1745-54. PubMed ID: 10775259
[No Abstract] [Full Text] [Related]
24. Calcium signaling-induced Smad3 nuclear accumulation induces acetylcholinesterase transcription in apoptotic HeLa cells.
Gao W; Zhu H; Zhang JY; Zhang XJ
Cell Mol Life Sci; 2009 Jul; 66(13):2181-93. PubMed ID: 19468687
[TBL] [Abstract][Full Text] [Related]
25. YTHDF2 governs muscle size through a targeted modulation of proteostasis.
Gilbert CJ; Rabolli CP; Golubeva VA; Sattler KM; Wang M; Ketabforoush A; Arnold WD; Lepper C; Accornero F
Nat Commun; 2024 Mar; 15(1):2176. PubMed ID: 38467649
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional coregulator SNW/SKIP: the concealed tie of dissimilar pathways.
Folk P; Půta F; Skruzný M
Cell Mol Life Sci; 2004 Mar; 61(6):629-40. PubMed ID: 15052407
[TBL] [Abstract][Full Text] [Related]
27. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
28. Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer.
Kanteti R; El-Hashani E; Dhanasingh I; Tretiakova M; Husain AN; Sharma S; Sharma J; Vokes EE; Salgia R
BMC Cancer; 2014 Mar; 14():185. PubMed ID: 24628993
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer.
Zhang Z; Liu D; Murugan AK; Liu Z; Xing M
Endocr Relat Cancer; 2014 Apr; 21(2):161-73. PubMed ID: 24243688
[TBL] [Abstract][Full Text] [Related]
30. NADPH Oxidase NOX4 Is a Critical Mediator of BRAF
Azouzi N; Cailloux J; Cazarin JM; Knauf JA; Cracchiolo J; Al Ghuzlan A; Hartl D; Polak M; Carré A; El Mzibri M; Filali-Maltouf A; Al Bouzidi A; Schlumberger M; Fagin JA; Ameziane-El-Hassani R; Dupuy C
Antioxid Redox Signal; 2017 May; 26(15):864-877. PubMed ID: 27401113
[TBL] [Abstract][Full Text] [Related]
31. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease.
Melo M; Gaspar da Rocha A; Batista R; Vinagre J; Martins MJ; Costa G; Ribeiro C; Carrilho F; Leite V; Lobo C; Cameselle-Teijeiro JM; Cavadas B; Pereira L; Sobrinho-Simões M; Soares P
J Clin Endocrinol Metab; 2017 Jun; 102(6):1898-1907. PubMed ID: 28323937
[TBL] [Abstract][Full Text] [Related]
32. Different expression of TSH receptor and NIS genes in thyroid cancer: role of epigenetics.
D'Agostino M; Sponziello M; Puppin C; Celano M; Maggisano V; Baldan F; Biffoni M; Bulotta S; Durante C; Filetti S; Damante G; Russo D
J Mol Endocrinol; 2014 Apr; 52(2):121-31. PubMed ID: 24353283
[TBL] [Abstract][Full Text] [Related]
33. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
34. BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism.
Durante C; Puxeddu E; Ferretti E; Morisi R; Moretti S; Bruno R; Barbi F; Avenia N; Scipioni A; Verrienti A; Tosi E; Cavaliere A; Gulino A; Filetti S; Russo D
J Clin Endocrinol Metab; 2007 Jul; 92(7):2840-3. PubMed ID: 17488796
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis of cancers derived from thyroid follicular cells.
Fagin JA; Krishnamoorthy GP; Landa I
Nat Rev Cancer; 2023 Sep; 23(9):631-650. PubMed ID: 37438605
[TBL] [Abstract][Full Text] [Related]
36. GLIS3 regulates transcription of thyroid hormone biosynthetic genes in coordination with other thyroid transcription factors.
Kang HS; Grimm SA; Jothi R; Santisteban P; Jetten AM
Cell Biosci; 2023 Feb; 13(1):32. PubMed ID: 36793061
[TBL] [Abstract][Full Text] [Related]
37. Ouabain Effects on Human Anaplastic Thyroid Carcinoma 8505C Cells.
Teixeira MP; Haddad NF; Passos EF; Andrade MN; Campos MLA; da Silva JMC; de Figueiredo CS; Giestal-de-Araujo E; de Carvalho DP; Miranda-Alves L; de Paiva LS
Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551653
[TBL] [Abstract][Full Text] [Related]
38. Positive
Huang S; Qi M; Tian T; Dai H; Tang Y; Huang R
Front Endocrinol (Lausanne); 2022; 13():959089. PubMed ID: 36407316
[TBL] [Abstract][Full Text] [Related]
39. Transcription Factor CREB3L1 Regulates the Expression of the Sodium/Iodide Symporter (NIS) in Rat Thyroid Follicular Cells.
Di Giusto P; Martín M; Funes Chabán M; Sampieri L; Nicola JP; Alvarez C
Cells; 2022 Apr; 11(8):. PubMed ID: 35455992
[TBL] [Abstract][Full Text] [Related]
40. Sox9 is involved in the thyroid differentiation program and is regulated by crosstalk between TSH, TGFβ and thyroid transcription factors.
López-Márquez A; Carrasco-López C; Martínez-Cano A; Lemoine P; Pierreux CE; Santisteban P
Sci Rep; 2022 Feb; 12(1):2144. PubMed ID: 35140269
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
